Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis

David R. Boulware, David B. Meya, Conrad Muzoora, Melissa A. Rolfes, Katherine Huppler Hullsiek, Abdu Musubire, Kabanda Taseera, Henry W. Nabeta, Charlotte Schutz, Darlisha A. Williams, Radha Rajasingham, Joshua Rhein, Friedrich Thienemann, Melanie W. Lo, Kirsten Nielsen, Tracy L. Bergemann, Andrew Kambugu, Yukari C. Manabe, Edward N. Janoff, Paul R. BohjanenGraeme Meintjes

Research output: Contribution to journalArticlepeer-review

263 Scopus citations

Abstract

BACKGROUND: Cryptococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Africa. Antiretroviral therapy (ART) is essential for survival; however, the question of when ART should be initiated after diagnosis of cryptococcal meningitis remains unanswered. METHODS: We assessed survival at 26 weeks among 177 human immunodeficiency virus-infected adults in Uganda and South Africa who had cryptococcal meningitis and had not previously received ART. We randomly assigned study participants to undergo either earlier ART initiation (1 to 2 weeks after diagnosis) or deferred ART initiation (5 weeks after diagnosis). Participants received amphotericin B (0.7 to 1.0 mg per kilogram of body weight per day) and fluconazole (800 mg per day) for 14 days, followed by consolidation therapy with fluconazole. RESULTS: The 26-week mortality with earlier ART initiation was significantly higher than with deferred ART initiation (45% [40 of 88 patients] vs. 30% [27 of 89 patients]; hazard ratio for death, 1.73; 95% confidence interval [CI], 1.06 to 2.82; P = 0.03). The excess deaths associated with earlier ART initiation occurred 2 to 5 weeks after diagnosis (P = 0.007 for the comparison between groups); mortality was similar in the two groups thereafter. Among patients with few white cells in their cerebrospinal fluid (<5 per cubic millimeter) at randomization, mortality was particularly elevated with earlier ART as compared with deferred ART (hazard ratio, 3.87; 95% CI, 1.41 to 10.58; P = 0.008). The incidence of recognized cryptococcal immune reconstitution inflammatory syndrome did not differ significantly between the earlier-ART group and the deferred-ART group (20% and 13%, respectively; P = 0.32). All other clinical, immunologic, virologic, and microbiologic outcomes, as well as adverse events, were similar between the groups. CONCLUSIONS: Deferring ART for 5 weeks after the diagnosis of cryptococcal meningitis was associated with significantly improved survival, as compared with initiating ART at 1 to 2 weeks, especially among patients with a paucity of white cells in cerebrospinal fluid.

Original languageEnglish (US)
Pages (from-to)2487-2498
Number of pages12
JournalNew England Journal of Medicine
Volume370
Issue number26
DOIs
StatePublished - 2014

Fingerprint Dive into the research topics of 'Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis'. Together they form a unique fingerprint.

Cite this